filgotinib (Compound)

Synonyms:1206101-20-3, Filgotinib, GLPG0634, 1206161-97-8, N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide, GLPG-0634, Filgotinib(GLPG0634), Filgotinib (GLPG0634), GS-6034 FREE BASE, 3XVL385Q0M, GPLG0634, N-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide, G146034, G-146034, Jyseleca, Filgotinib [INN], N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide., Filgotinib [USAN:INN], UNII-3XVL385Q0M, GLPG 0634, N-(5-{4-[(1,1-Dioxidothiomorpholin-4-Yl)methyl]phenyl}[1,2,4]triazolo[1,5-A]pyridin-2-Yl)cyclopropanecarboxamide, Filgotinib (USAN/INN), FILGOTINIB [USAN], Filgotinib; GPLG0634, FILGOTINIB [WHO-DD], N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide, SCHEMBL253559, Filgotinib pound GLPG0643), GTPL7913, CHEMBL3301607, AMY3802, DTXSID80152935, EX-A741, BDBM103727, HMS3653P15, HMS3673E07, BCP08496, MFCD20527867, NSC800100, s7605, AKOS025291103, CCG-268951, DB14845, NSC-800100, SB16799, NCGC00345855-01, NCGC00345855-07, AS-16295, BF159062, DA-33603, DA-33604, HY-18300, FT-0700114, FT-0761510, SW220020-1, A14232, D10871, P12798, US8563545, 1, EN300-7419864, A892158, J-690063, SYN1158;GLPG 0634; GLPG-0634; Filgotinib, Q19904163, Z2037280227, CYCLOPROPANECARBOXAMIDE, N-(5-(4-((1,1-DIOXIDO-4-THIOMORPHOLINYL)METHYL)PHENYL)(1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)-, GLPG0634;N-[5-[4-[(1,1-Dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide, N-(5-(4-((1,1-OXO-.LAMBDA.6-THIOMORPHOLIN-4-YL)METHYL)PHENYL((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-2-YL)CYCLOPROPANECARBOXAMIDE, N-(5-{4-[(1,1-dioxo-1lambda6-thiomorpholin-4-yl)methyl]phenyl}-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide

Pubchem:PUBCHEM:49831257

Id:ca5546e9-566b-5d18-b018-b3a98d53e454

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View filgotinib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for filgotinib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with filgotinib.

Results found

Linked to

	Label	Description
	BRD-K16803204-001-01-6 Substance (Entity type)	A Substance
	DCSTRUCT ID 05419 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05419; PubChem_CID:49831257, FILE=drugcentral_drug_05419.json)
	filgotinib (1647f79b-4e99-4423-8f47-9f653a301cfc) Collection (Entity type)	Metadatata for filgotinib
	filgotinib negatively regulates RARRES2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	filgotinib positively regulates PFKL Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	filgotinib indication Proliferative arthritis Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	filgotinib negatively regulates IFI6 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	filgotinib negatively regulates SCGB2A1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	filgotinib positively regulates SDC2 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	filgotinib negatively regulates ASS1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS